NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nucleai

Nucleai

Private
Chicago, IllinoisHealthcare & Life Scienceshttps://nucleai.ai/

Last Round

Series B

Extension

Apr 3, 2024

Total Funding Raised

$58.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Nucleai is a biotechnology company that offers a spatial biology software platform designed to enhance precision medicine through advanced artificial intelligence and machine learning technologies.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Drug Discovery, Medical AI, Clinical Trials, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS

AI Layer

Application

Keywords

spatial biologyspatial AIbiomarker discoverydigital pathologypatient stratificationcomputational pathologyspatial proteomicsantibody-drug conjugateADCclinical trial designcompanion diagnosticsprecision medicineAI pathologytissue imagingbiotech AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nucleai Comparables

Compare Nucleai with similar companies based on industry and business-model similarity.

Nucleai comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Aignostics
87%
Panakeia
84%
Visiopharm
82%

Nucleai Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionApr 3, 2024
Series BMar 22, 2022
Series AJul 7, 2020
SeedMar 5, 2018

Key People

Founding team and executive leadership

Avi Veidman

CEO

Executive Team

Golan Mizrahi

CFO

Executive Team

Dudi Benayoun

Chief Operating Officer (COO)

Executive Team

Eliron Amir

Chief Product Officer

Executive Team

Nucleai Investors

Notable investors and investment history

Nucleai investors
InvestorRounds
S32Series B Extension, Series B
Fosun RZ CapitalSeries B Extension, Series B
Grove VenturesSeries A, Series B Extension, Series B, Seed
M VenturesSeries B Extension
Vvc AdvisorsSeries B
Fosun InternationalSeries B
Vertex Ventures IsraelSeries A, Series B Extension, Series B, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Integrated spatial proteomics solution for drug development.

  • Apr 15, 2026

    Integrated spatial proteomics solution launched with Sirona Dx.

Nucleai Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nucleai Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nucleai's valuation, stock price, and market status.

Firmographic Details

HeadquartersChicago, Illinois
Employee Range67
Year Founded2018
Last FundingApr 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.